{"filing":{"accession_number":"0001493152-26-028628","cik":"0001995704","ticker":"CUPR","company_name":"Cuprina Holdings (Cayman) LTD","form":"6-K","filing_date":"2026-06-15","report_date":null,"primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1995704/000149315226028628/form6-k.htm"},"events":[{"id":12283,"run_id":10848,"accession_number":"0001493152-26-028628","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Cuprina announced receipt of U.S. FDA 510(k) clearance for MEDIFLY Maggots, a medical-grade Lucilia cuprina larvae product for maggot debridement therapy. This is a significant regulatory milestone and product approval that enables commercial launch in the U.S. market. While not a discrete M\u0026A, financing, or governance event, this regulatory clearance is a material operational and strategic achievement that would affect a reasonable investor's assessment of the company's product portfolio and market opportunities, particularly as it positions Cuprina as the only company holding FDA clearance for both maggot species used in MDT.","company_name":"Cuprina Holdings (Cayman) LTD","ticker":"CUPR","filing_date":"2026-06-15","form":"6-K","submitted_at":null,"items":[{"id":9092,"accession_number":"0001493152-26-028628","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Cuprina announced receipt of U.S. FDA 510(k) clearance for MEDIFLY Maggots, a medical-grade Lucilia cuprina larvae product for maggot debridement therapy. This is a significant regulatory milestone and product approval that enables commercial launch in the U.S. market. While not a discrete M\u0026A, financing, or governance event, this regulatory clearance is a material operational and strategic achievement that would affect a reasonable investor's assessment of the company's product portfolio and market opportunities, particularly as it positions Cuprina as the only company holding FDA clearance for both maggot species used in MDT.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:33:48.886325+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9092,"accession_number":"0001493152-26-028628","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Cuprina announced receipt of U.S. FDA 510(k) clearance for MEDIFLY Maggots, a medical-grade Lucilia cuprina larvae product for maggot debridement therapy. This is a significant regulatory milestone and product approval that enables commercial launch in the U.S. market. While not a discrete M\u0026A, financing, or governance event, this regulatory clearance is a material operational and strategic achievement that would affect a reasonable investor's assessment of the company's product portfolio and market opportunities, particularly as it positions Cuprina as the only company holding FDA clearance for both maggot species used in MDT.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:33:48.886325+00:00","company_name":"Cuprina Holdings (Cayman) LTD","ticker":"CUPR","filing_date":"2026-06-15"}]}